Multiple Myeloma

Latest News

Video Series

Ajay K. Nooka, MD, MPH, FACP

Dr Nooka on Integrating Bispecific Antibodies Into the Community Treatment Paradigm for Multiple Myeloma

Ajai Chari, MD

Dr Chari on the Risks and Benefits Associated With Earlier CAR T Use in R/R Multiple Myeloma

Saad Z. Usmani, MD, MBA, FACP, FASCO

Dr Usmani on Challenges With Bispecifics and CAR T-Cell Therapies in Multiple Myeloma

Amrita Krishnan, MD

Dr Krishnan on Maintenance Approaches in Transplant-Ineligible Multiple Myeloma

A panel of 5 experts on multiple myeloma

Treatment Considerations and Sequencing in Multiple Myeloma

A panel of 5 experts on multiple myeloma

CAR T-Cell Therapy in Multiple Myeloma: Role in the Treatment Landscape

A panel of 5 experts on multiple myeloma

GPRC5D-Targeting Bispecifics in Multiple Myeloma

A panel of 5 experts on multiple myeloma

Adverse Effects Related to Bispecifics in Multiple Myeloma

A panel of 5 experts on multiple myeloma

Step-Up Dosing Practices for Bispecifics in Multiple Myeloma

A panel of 5 experts on multiple myeloma

Real-World Evidence and Selecting Optimal Bispecifics in Multiple Myeloma

Latest Videos

$Rahul Banerjee, MD, FACP, discusses the FDA accelerated approval of iberdomide plus daratumumab/dexamethasone in relapsed/refractory myeloma.$

Dr Banerjee on the FDA Approval of Iberdomide Plus Daratumumab/Dexamethasone in R/R Myeloma

$Adam D. Cohen, MD, discusses the mechanism of action of cevostamab in relapsed/refractory multiple myeloma.$

Dr Cohen on the Mechanism of Action of Cevostamab in R/R Myeloma

Rafael Fonseca, MD, discusses how FISH, NGS, and minimal residual disease testing guide risk stratification and treatment in multiple myeloma.

Dr Fonseca on the Role of Molecular Profiling in Multiple Myeloma Management

$Adam D. Cohen, MD, discusses future research directions for cevostamab in relapsed/refractory multiple myeloma.$

Dr Cohen on Future Research Avenues for Cevostamab in R/R Myeloma

$Adam D. Cohen, MD, discusses phase 1 efficacy data for cevostamab in relapsed/refractory multiple myeloma.$

Dr Cohen on Phase 1 Efficacy Data for Cevostamab in R/R Myeloma

Adam D. Cohen, MD, discusses the potential role of FcRH5 as a target and the ongoing investigation of cevostamab in multiple myeloma.

Dr Cohen on FcRH5 as a Therapeutic Target in Multiple Myeloma

Claudio Cerchione, MD, PhD, discusses the significance of the FDA approval of subcutaneous isatuximab in multiple myeloma.

Dr Cerchione on the FDA Approval of Subcutaneous Isatuximab in Myeloma

$Andrew Spencer, MBBS, FRACP, FRCPA, DM, discusses the potential role for in vivo CAR T-cell therapy in relapsed/refractory multiple myeloma.$

Dr Spencer on the Potential Role for In Vivo CAR T-Cell Therapy in Myeloma

Andrew Spencer, MBBS, FRACP, FRCPA, DM, discusses efficacy data for the in vivo CAR T-cell therapy KLN-1010 in multiple myeloma.

Dr Spencer on Early Efficacy Data for In Vivo CAR T-Cell Therapy in R/R Myeloma

Andrew Spencer, MBBS, FRACP, FRCPA, DM, discusses key features of in vivo CAR T-cell therapy in multiple myeloma.

Dr Spencer on Differentiating Factors for In Vivo CAR T-Cell Therapy in Myeloma

Shorts

Joshua Richter, MD

Joshua Richter, MD, Answers Rahul Banerjee, MD, FACP

18 days ago

by

Joshua Richter, MD

Joshua Richter, MD

Joshua Richter, MD, Discusses Multiple Myeloma Vaccines

19 days ago

by

Joshua Richter, MD, Tisch Cancer Center at Mount Sinai

Where Iberdomide Plus Daratumumab and Dexamethasone Fits in the R/R Myeloma Paradigm

Where Iberdomide Plus Daratumumab and Dexamethasone Fits in the R/R Myeloma Paradigm

24 days ago

by

Rahul Banerjee, MD

Rafael Fonseca, MD, discusses the evolution of molecular testing in multiple myeloma and its role in risk stratification and treatment decision-making.

Navigating Molecular Testing in Multiple Myeloma

a month ago

by

Rafael Fonseca, MD

Targeting FcRH5 in Multiple Myeloma

Targeting FcRH5 in Multiple Myeloma

a month ago

by

Adam D. Cohen, MD

Why Early CAR T-Cell Therapy Is a Game-Changer in Myeloma

Why Early CAR T-Cell Therapy Is a Game-Changer in Myeloma

a month ago

by

Hamza Hashmi, MD

Peter Voorhees, MD

The Significance of the MajesTEC-9 Trial in R/R Myeloma

2 months ago

by

Peter Voorhees, MD

Assessing Data for In Vivo CAR T-Cell Therapy in Myeloma

Assessing Data for In Vivo CAR T-Cell Therapy in Myeloma

2 months ago

by

Andrew Spencer, MBBS, FRACP, FRCPA, DM

Noa Biran, MD

Diving into Key Multiple Myeloma Data From ASCO 2026

2 months ago

by

Noa Biran, MD

Andrew Spencer, MBBS, FRACP, FRCPA, DM

The Potential of In Vivo CAR T-Cell Therapy in Multiple Myeloma

2 months ago

by

Andrew Spencer, MBBS, FRACP, FRCPA, DM

Podcasts

$Sagar Lonial, MD, FACP, FASCO, shares the significance of the FDA approval of iberdomide/daratumumab/dexamethasone in replased/refractory multiple myeloma.$

August 27, 2026

FDA Approval Insights: Iberdomide-Based Therapy Adds Another Option for R/R Myeloma: With Sagar Lonial, MD, FACP, FASCO

Douglas W. Sborov, MD, MS, discussed the FDA approval of isatuximab for subcutaneous injection in multiple myeloma indications.

FDA Approval Insights: Subcutaneous Isatuximab Via an On-Body Delivery System Represents a “Game-Changer” in Multiple Myeloma: With Douglas W. Sborov, MD, MS

Oncology Unplugged

Quadruplet Regimens and T-Cell Redirection Are on the Map of Myeloma Management Strategies: With Chandler Park, MD; Muhamed Baljevic, MD, FACP

Noa Biran, MD, breaks down key multiple myeloma data shared at the 2026 ASCO Annual Meeting.

Unpacking Key Multiple Myeloma Data From ASCO 2026: With Noa Biran, MD (VIDEO)

Joshua Richter, MD, previews some of the most anticipated multiple myeloma presentations ahead of the 2026 EHA Congress.

Previewing Key Myeloma Presentations to Watch at EHA 2026: With Joshua Richter, MD

Saad Z. Usmani, MD, MBA, FACP, FASCO, discusses the significance of the FDA approval of daratumumab plus VRd for the treatment of newly diagnosed, transplant-ineligible multiple myeloma.

FDA Approval Insights: SC Daratumumab Plus VRd Provides Additional Treatment Avenue in Transplant-Ineligible, Newly Diagnosed Myeloma: With Saad Z. Usmani, MD, MBA, FACP, FASCO

Subcutaneous Isatuximab via On-Body Injector Has Noninferior Efficacy vs IV Delivery in Myeloma: With Sikander Aila

January 30, 2026

Subcutaneous Isatuximab via On-Body Injector Has Noninferior Efficacy vs IV Delivery in Myeloma: With Sikander Ailawadhi, MD; and Beth Faiman, CNP, PhD

Rahul Banerjee, MD, FACP, assistant professor, Clinical Research Division, Fred Hutchinson Cancer Center; assistant professor, Division of Hematology and Oncology, University of Washington

January 16, 2026

Emerging CELMoDs Set New Standards for Efficacy and Tolerability in Myeloma: With Rahul Banerjee, MD, FACP

Pooja M. Phull, MD, hematologist/oncologist, John Theurer Cancer Center, Hackensack University Medical Center

December 18, 2025

Microbiome Profiling Highlights Impact of Butyrate Loss on Post-Transplant Outcomes in Multiple Myeloma: With Pooja M. Phull, MD

Joshua Richter, MD, associate professor, medicine, The Tisch Cancer Institute; director, Multiple Myeloma, Blavatnik Family Chelsea Medical Center, Mount Sinai

November 28, 2025

Cevostamab-Based Regimens Usher In the Next Wave of Bispecific Antibody Strategies in R/R Myeloma: With Joshua Richter, MD

CME Content

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Arkansas Association of Cancer Professionals

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Arkansas Association of Cancer Professionals

Kamel Abou Hussein, MD; Yelda Nouri, MD

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Rhode Island Oncology Society

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Rhode Island Oncology Society

Aditya Bardia, MD, MPH, FASCO; Benjamin Scheier, MD

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Iowa Oncology Society

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Iowa Oncology Society

Aditya Bardia, MD, MPH, FASCO; Priya Kumar, MBBS, MS

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Empire State Hematology & Oncology Society

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Empire State Hematology & Oncology Society

Aditya Bardia, MD, MPH, FASCO; Mohammad F. Ali, MD

𝘔𝘌𝘛 Alterations in NSCLC: Applying Diagnostic Advances and Targeted Therapies in a New Era of Treatment

𝘔𝘌𝘛 Alterations in NSCLC: Applying Diagnostic Advances and Targeted Therapies in a New Era of Treatment

Jonathan Goldman, MD; Sanja Dacic, MD, PhD; Deborah Doroshow, MD, PhD; Anne S. Tsao, MD, MBA

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | South Carolina Oncology Society

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | South Carolina Oncology Society

Kamel Abou Hussein, MD; Kate Baxstrom, MD

Community Oncology Connections™: Advancing Precision Testing and HER2-Targeted Care for Gastroesophageal Adenocarcinoma – Minnesota

Community Oncology Connections™: Advancing Precision Testing and HER2-Targeted Care for Gastroesophageal Adenocarcinoma – Minnesota

Geoffrey Ku, MD; Jack W. Erter III, MD, MMHC

Community Oncology Connections™: How Can We Optimize the Use of Oral SERDs in the Community Oncology Setting? Best Practices for HR+/HER2– Breast Cancer | Texas Society of Clinical Oncology

Community Oncology Connections™: How Can We Optimize the Use of Oral SERDs in the Community Oncology Setting? Best Practices for HR+/HER2– Breast Cancer | Texas Society of Clinical Oncology

Ajit K. Bisen, MD, MBA; Virginia Kaklamani, MD, DSc

Community Oncology Connections™: Advancing Precision Testing and HER2-Targeted Care for Gastroesophageal Adenocarcinoma – North Carolina

Community Oncology Connections™: Advancing Precision Testing and HER2-Targeted Care for Gastroesophageal Adenocarcinoma – North Carolina

Syma Iqbal, MD; Benjamin Scheier, MD

Community Oncology Connections™: Advancing Precision Testing and HER2-Targeted Care for Gastroesophageal Adenocarcinoma – West Virginia

Community Oncology Connections™: Advancing Precision Testing and HER2-Targeted Care for Gastroesophageal Adenocarcinoma – West Virginia

Sunnie S. Kim, MD; Kellie D. Spector, MD

Community Oncology Connections™: Bridging Academic and Community Connections to Advance Precision and Targeted Care in NF1 Plexiform Neurofibromas | Nevada Oncology Society

Community Oncology Connections™: Bridging Academic and Community Connections to Advance Precision and Targeted Care in NF1 Plexiform Neurofibromas | Nevada Oncology Society

Amy E. Armstrong, MD; Phioanh “Leia” Nghiemphu, MD

Kansas Society of Clinical Oncology

Kansas Society of Clinical Oncology

1 Session is Available!

Community Oncology Connections™: Bridging Academic and Community Connections to Advance Precision and Targeted Care in NF1 Plexiform Neurofibromas | Rhode Island Oncology Society

Community Oncology Connections™: Bridging Academic and Community Connections to Advance Precision and Targeted Care in NF1 Plexiform Neurofibromas | Rhode Island Oncology Society

Daniela A. Bota, MD, PhD; Kurt C. Demel, MD, MBA

27th Annual International Lung Cancer Congress®

27th Annual International Lung Cancer Congress®

Roy S. Herbst, MD, PhD; Sandip Patel, MD, FASCO; Heather A. Wakelee, MD, FASCO

Community Practice Connections™: Enhancing Melanoma Outcomes With Intratumoral Oncolytic Immunotherapy–Strategies for the Multidisciplinary Team

Community Practice Connections™: Enhancing Melanoma Outcomes With Intratumoral Oncolytic Immunotherapy–Strategies for the Multidisciplinary Team

Yana G. Najjar, MD; Sapna Patel, MD

Community Oncology Connections™: How Can We Optimize the Use of Oral SERDs in the Community Oncology Setting? Best Practices for HR+/HER2– Breast Cancer | Tennessee Oncology Practice Society

Community Oncology Connections™: How Can We Optimize the Use of Oral SERDs in the Community Oncology Setting? Best Practices for HR+/HER2– Breast Cancer | Tennessee Oncology Practice Society

Virginia Kaklamani, MD, DSc; Denise Yardley, MD, GCRA

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Washington State Medical Oncology Society

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Washington State Medical Oncology Society

Kamel Abou Hussein, MD; Yan Ji, MD, PhD

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Colorado Oncology Society

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Colorado Oncology Society

Kamel Abou Hussein, MD; Kit Y Lu, MD

Community Oncology Connections™: Bridging Academic and Community Connections to Advance Precision and Targeted Care in NF1 Plexiform Neurofibromas | Wisconsin Association of Hematology and Oncology

Community Oncology Connections™: Bridging Academic and Community Connections to Advance Precision and Targeted Care in NF1 Plexiform Neurofibromas | Wisconsin Association of Hematology and Oncology

Daniela A. Bota, MD, PhD; Benjamin Scheier, MD

Community Oncology Connections™: Advancing Precision Testing and HER2-Targeted Care for Gastroesophageal Adenocarcinoma – Montana/Wyoming

Community Oncology Connections™: Advancing Precision Testing and HER2-Targeted Care for Gastroesophageal Adenocarcinoma – Montana/Wyoming

Syma Iqbal, MD; Shiven B. Patel, MD, MBA, FACP

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Indiana Oncology Society

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Indiana Oncology Society

Kamel Abou Hussein, MD; Sushil Bhardwaj, MD, FACP

Tennessee Oncology Practice Society

Tennessee Oncology Practice Society

2 Sessions are Available!

Washington State Medical Oncology Society

Washington State Medical Oncology Society

2 Sessions are Available!

Louisiana Oncology Society

Louisiana Oncology Society

3 Sessions are Available!

Hot Seat: How Experts Are Integrating the Latest Practice-Changing Data Into Their Breast Cancer Clinics

Hot Seat: How Experts Are Integrating the Latest Practice-Changing Data Into Their Breast Cancer Clinics

Tiffany A. Traina, MD, FASCO; Nour Abuhadra, MD; Joshua Z. Drago, MD, MS; Ruth O’Regan, MD; Vered Stearns, MD, FASCO; Neil Vasan, MD, PhD; Anna Weiss, MD

Biomarker Testing in HER2+ GEA: Diagnosis and Treatment Implications

Biomarker Testing in HER2+ GEA: Diagnosis and Treatment Implications

Rahul Gosain, MD, MBA; Rohit Gosain, MD; Rutika Mehta, MD, MPH

Hot Seat: Converging Lines in the Management of RAS-Altered Cancers

Hot Seat: Converging Lines in the Management of RAS-Altered Cancers

Shubham Pant, MD, MBBS; Alison Schram, MD; Helena Yu, MD

(CME Track) Tackling Oncologic Emergencies in Patients Treated With High-Dose Methotrexate

(CME Track) Tackling Oncologic Emergencies in Patients Treated With High-Dose Methotrexate

Shazia Nakhoda, MD; Shruti Gupta, MD, MPH; Anitha Varghese, MSN, APRN, AGPCNP-C

Cases & Conversations™: Unmasking Epithelioid Sarcoma – Enhancing Early Diagnosis and Multidisciplinary Care

Cases & Conversations™: Unmasking Epithelioid Sarcoma – Enhancing Early Diagnosis and Multidisciplinary Care

Mark Agulnik, MD; Mrinal M. Gounder, MD; Sandra D’Angelo, MD; Sujana Movva, MD

The Rise of Novel HER2-Targeting Therapies in GEA: Mechanisms and Clinical Data

The Rise of Novel HER2-Targeting Therapies in GEA: Mechanisms and Clinical Data

Rahul Gosain, MD, MBA; Rohit Gosain, MD

Beyond Primary End Points: Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer

Beyond Primary End Points: Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer

Seth A. Wander, MD, PhD; Marla D. Lipsyc-Sharf, MD

Show Me the Data™: Personalizing First-Line and Maintenance Therapy in HER2+ Metastatic Breast Cancer to Extend Survival and Elevate Quality of Life

Show Me the Data™: Personalizing First-Line and Maintenance Therapy in HER2+ Metastatic Breast Cancer to Extend Survival and Elevate Quality of Life

Sara A. Hurvitz, MD, FACP; Rena Callahan, MD; Michelle Melisko, MD; Paolo Tarantino, MD, PhD

Revolutionizing TGCT Care with Multidisciplinary Perspectives and Cutting-Edge Targeted Therapies

Revolutionizing TGCT Care with Multidisciplinary Perspectives and Cutting-Edge Targeted Therapies

Mark Agulnik, MD; Lee M. Zuckerman, MD

Optimizing Multidisciplinary Care in TGCT

Optimizing Multidisciplinary Care in TGCT

Mark Agulnik, MD; Lee M. Zuckerman, MD

Diagnosis and Management of TGCT

Diagnosis and Management of TGCT

Mark Agulnik, MD; Lee M. Zuckerman, MD

Medical Crossfire®: The Who, When, and How of TROP2-Targeting ADCs, ICIs, and PARP inhibition in Triple-Negative Breast Cancer

Medical Crossfire®: The Who, When, and How of TROP2-Targeting ADCs, ICIs, and PARP inhibition in Triple-Negative Breast Cancer

Hope S. Rugo, MD; Alison K. Conlin, MD; Marleen Kok, MD, PhD; Heather McArthur, MD, MPH

Real-World Insights on Advances in the Management of Myeloproliferative Neoplasms: How the Experts Apply the Latest Developments to Clinical Practice

Real-World Insights on Advances in the Management of Myeloproliferative Neoplasms: How the Experts Apply the Latest Developments to Clinical Practice

Naveen Pemmaraju, MD; Shannon Elf, PhD; Angela Fleischman, MD, PhD; Bethan Psaila, MD

SimulatEd™: A Roadmap to Personalized Care Plans and Shared Decision-Making in Low-Grade Serous Ovarian Cancer

Case-based Simulation

SimulatEd™: A Roadmap to Personalized Care Plans and Shared Decision-Making in Low-Grade Serous Ovarian Cancer

Rachel N. Grisham, MD

Tumor Board™: Navigating a New Era of Innovation and Expanding Options in NMIBC

Tumor Board™: Navigating a New Era of Innovation and Expanding Options in NMIBC

Archan Khandekar, MD; Wassim Kassouf, MD, CM, FRCSC; Jen-Jane Liu, MD

Expert Illustrations & Commentaries: Translating the Science of Bispecific Antibodies in Solid Tumors – From Mechanisms to Emerging Data

Expert Illustrations & Commentaries: Translating the Science of Bispecific Antibodies in Solid Tumors – From Mechanisms to Emerging Data

John V. Heymach, MD, PhD; Anne S. Tsao, MD, MBA, FASCO, FACHE

“D” is for Diagnosis: Decoding a Difficult Thoracic Malignancy—Piecing Together a Rare Diagnosis, Preparing for Tomorrow’s Treatments

“D” is for Diagnosis: Decoding a Difficult Thoracic Malignancy—Piecing Together a Rare Diagnosis, Preparing for Tomorrow’s Treatments

Aakash Desai, MD, MPH; Ibiayi Dagogo-Jack, MD, FASCO; Patrick Forde, MD, PhD

Combination Approaches in PD-L1–Positive mTNBC: Practice-Changing Frontline Evidence

Combination Approaches in PD-L1–Positive mTNBC: Practice-Changing Frontline Evidence

Rahul Gosain, MD, MBA; Rohit Gosain, MD; Sherene Loi, MMBS (Hons), FRACP, PhD, FAHMS

First-Line ADC Monotherapy in mTNBC: Addressing Unmet Needs in Immunotherapy-Ineligible Populations

First-Line ADC Monotherapy in mTNBC: Addressing Unmet Needs in Immunotherapy-Ineligible Populations

Rahul Gosain, MD, MBA; Rohit Gosain, MD; Adam Brufsky, MD, PhD

Tumor Board: Translating HER2 and TROP2 Innovations to Transform NSCLC Care

Tumor Board: Translating HER2 and TROP2 Innovations to Transform NSCLC Care

Jacob Sands, MD; Marina Chiara Garassino, MD; Eric K. Singhi, MD

More News

The FDA approved daraxonrasib for pancreatic cancer, cleared zanidatamab-based regimens for HER2-positive gastric cancer, and more.

The OncFive: Top Oncology Articles for the Week of 8/23

ByOncLive Staff

August 29th 2026

The FDA approved daraxonrasib for pancreatic cancer, cleared zanidatamab-based regimens for HER2-positive gastric cancer, and more.

Multiple Myeloma | Image Credit: © LELISAT - stock.adobe.com

Prophylactic Measures and Access Gaps Define the Push to Deliver Bispecifics Closer to Home in Myeloma

ByOncLive Staff

August 26th 2026

An OncLive Scientific Interchange and Workshop examined community integration of bispecific antibodies in multiple myeloma.

Multiple Myeloma | Image Credit: © LASZLO - stock.adobe.com

MOMENTUM Trial Aims to Add Further Evidence for Cemsidomide in R/R Myeloma

August 24th 2026

Sagar Lonial, MD, FACP, FASCO, and Sikander Ailawadhi, MD, discuss the investigation of cemsidomide in relapsed/refractory multiple myeloma.

Multiple Myeloma | Image Credit: © LASZLO - stock.adobe.com

Teclistamab-Based Induction Elicits High MRD Negativity Rates in Transplant-Eligible Newly Diagnosed Myeloma

ByOncLive Staff

August 24th 2026

Teclistamab-based induction generated a 91.8% MRD-negative complete response rate with a manageable safety profile in multiple myeloma.

Multiple Myeloma | Image Credit: © Tongpoon - stock.adobe.com

European Commission Approves Teclistamab Plus Daratumumab for R/R Myeloma

ByOncLive Staff

August 21st 2026

The European Commission approved teclistamab plus daratumumab for relapsed/refractory multiple myeloma after at least 1 prior therapy, offering the regimen as early as second line.

Multiple Myeloma | Image Credit: © TheWaterMeloonProjec - stock.adobe.com

NMA Associates MRD-Negative CR With PFS in Earlier-Line R/R Myeloma

ByOncLive Staff

August 18th 2026

An analysis of 12 randomized trials validated MRD-negative CR as a surrogate for PFS in earlier-line relapsed/refractory multiple myeloma.

The top 5 OncLive TV videos of the week cover insights in multiple myeloma, melanoma, ovarian cancer, prostate cancer, and hepatocellular carcinoma.

Five Under 5: Top Oncology Videos for the Week of 8/9

ByOncLive Staff

August 16th 2026

The top 5 OncLive TV videos of the week cover insights in multiple myeloma, melanoma, ovarian cancer, prostate cancer, and hepatocellular carcinoma.

Dive into the Data Supporting the FDA Approval of Iberdomide Plus Daratumumab/Dexamethasone in R/R Myeloma

Dive into the Data Supporting the FDA Approval of Iberdomide Plus Daratumumab/Dexamethasone in R/R Myeloma

ByOncLive Staff

August 16th 2026

Data from EXCALIBER-RRMM supported FDA accelerated approval of iberdomide plus daratumumab/dexamethasone in R/R multiple myeloma.

The FDA approved iberdomide-based therapy for relapsed myeloma, rejected a neuroendocrine tumor therapy, and more.

The OncFive: Top Oncology Articles for the Week of 8/9

ByOncLive Staff

August 15th 2026

The FDA approved iberdomide-based therapy for relapsed myeloma, rejected a neuroendocrine tumor therapy, and more.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

OncLive Weekly News Quiz (8/14/2026): Did You Catch This Week's Myeloma, Lung Cancer, and Polycythemia Vera Updates?

ByOncLive Staff

August 14th 2026

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

FDA

FDA Approves Iberdomide Plus Daratumumab/Dexamethasone for R/R Myeloma

August 13th 2026

The FDA approved iberdomide plus daratumumab and dexamethasone for relapsed/refractory multiple myeloma.

catalin - stock.adobe.com

Revisit Every OncLive On Air Episode From July 2026

ByOncLive Staff

August 9th 2026

In case you missed any, read a recap of the episodes of OncLive On Air that aired in July 2026.

The top 5 OncLive TV videos of the week cover insights in melanoma, prostate cancer, breast cancer, multiple myeloma, and small cell lung cancer.

Five Under 5: Top Oncology Videos for the Week of 8/2

ByOncLive Staff

August 9th 2026

The top 5 OncLive TV videos of the week cover insights in melanoma, prostate cancer, breast cancer, multiple myeloma, and small cell lung cancer.

Adam D. Cohen, MD

Phase 1 Data Set the Stage for Further Exploration of Cevostamab in R/R Myeloma

August 4th 2026

Adam D. Cohen, MD, overviews phase 1 findings for cevostamab and outlines future research directions for the agent in relapsed/refractory multiple myeloma.

The FDA accepted an NDA for daraxonrasib in metastatic pancreatic cancer, approved zidesamtinib in pretreated ROS1-positive NSCLC, and more.

The OncFive: Top Oncology Articles for the Week of 7/19

ByOncLive Staff

July 26th 2026

The FDA accepted an NDA for daraxonrasib in metastatic pancreatic cancer, approved zidesamtinib in pretreated ROS1-positive NSCLC, and more.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

OncLive Weekly News Quiz (7/24/2026): Did You Miss Crucial Pancreatic, Lung, and Prostate Cancer Updates?

ByOncLive Staff

July 24th 2026

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

Multiple Myeloma | Image Credit: © LELISAT - stock.adobe.com

Teclistamab Plus Talquetamab Yields Significant Survival Benefits in Earlier-Line R/R Myeloma

ByOncLive Staff

July 23rd 2026

Teclistamab plus talquetamab met the primary PFS end point and improved overall survival in relapsed/refractory multiple myeloma in MonumenTAL-6.

The top 5 OncLive TV videos of the week cover insights in bladder cancer, chronic myeloid leukemia, multiple myeloma, pancreatic cancer, and chronic lymphocytic leukemia.

Five Under 5: Top Oncology Videos for the Week of 7/12

ByOncLive Staff

July 19th 2026

The top 5 OncLive TV videos of the week cover insights in bladder cancer, chronic myeloid leukemia, multiple myeloma, pancreatic cancer, and chronic lymphocytic leukemia.

The FDA approved gedatolisib in PIK3CA wild-type breast cancer, granted full approval to selpercatinib in RET fusion+ tumors, and more.

The OncFive: Top Oncology Articles for the Week of 7/12

ByOncLive Staff

July 18th 2026

The FDA approved gedatolisib in PIK3CA wild-type breast cancer, granted full approval to selpercatinib in RET fusion+ tumors, and more.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

OncLive Weekly News Quiz (7/17/2026): Did You Catch Important Milestones in Breast Cancer and Myeloma?

ByOncLive Staff

July 17th 2026

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

Experts shared the key data that stood out in hematologic oncology at the 2026 ASCO Annual Meeting.

Experts Unpack Crucial Hematologic Oncology Data From ASCO 2026

July 16th 2026

Experts shared the key data that stood out in hematologic oncology at the 2026 ASCO Annual Meeting.

Multiple Myeloma | Image Credit: © LASZLO - stock.adobe.com

Access, Sequencing Considerations Remain Key Focal Points for CAR T-Cell Therapy in R/R Myeloma

July 13th 2026

An OncLive Scientific Interchange and Workshop covered sequencing, toxicity management, and access barriers for CAR T-cell therapy in multiple myeloma.

EHA 2026 | Image Credit: © Tongpoon - stock.adobe.com

Dive Into Key Data and Presentations From EHA 2026

ByOncLive Staff

July 13th 2026

Readouts across LBCL, relapsed/refractory myeloma, and CALR-mutated myelofibrosis anchored the hematology data presented at EHA 2026.

FDA

FDA Accepts NDA for Mezigdomide Plus Kd in R/R Myeloma

ByOncLive Staff

July 13th 2026

The FDA accepted a new drug application for mezigdomide plus carfilzomib and dexamethasone for relapsed/refractory multiple myeloma.

Cancer | Image Credit: © catalin - stock.adobe.com

Revisit Every OncLive On Air Episode From June 2026

ByAshling Wahner

July 11th 2026

In case you missed any, check out our recap of the episodes of OncLive On Air that aired in June 2026.

Trending on OncLive

FDA Approves Camizestrant Plus a CDK4/6 Inhibitor for Emergent ESR1-Mutated HR+, HER2– Advanced Breast Cancer

Five Under 5: Top Oncology Videos for the Week of 8/31/26

B7-H4–Targeted ADCs Signal a New Frontier for Platinum-Resistant Ovarian and Endometrial Cancer

The OncFive: Top Oncology Articles for the Week of 8/30

Ivonescimab Meets OS End Point vs Pembrolizumab in First-Line PD-L1+ NSCLC